These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25566590)

  • 21. Trends in Implementation of Loading Dose of Voriconazole from 2010 to 2019 and Influencing Factors of Loading Dose Based on a Japanese Administrative Claim Database: A Retrospective Cohort Study.
    Inose R; Goto R; Shimoki M; Ohmagari N; Muraki Y
    Biol Pharm Bull; 2023; 46(12):1838-1841. PubMed ID: 38044104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring and use of an adjusted body weight strategy for high-dose voriconazole therapy.
    Richards PG; Dang KM; Kauffman CA; Stalker KL; Sudekum D; Kerr L; Brinker-Bodley M; Cheriyan B; West N; Collins CD; Polega S; Malani AN
    J Antimicrob Chemother; 2017 Apr; 72(4):1178-1183. PubMed ID: 28108679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.
    Boast A; Curtis N; Cranswick N; Gwee A
    J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic Drug Monitoring of Oral Voriconazole in an Infant Less than Six Months of Age and Pharmacokinetics Changes Induced by Development of CYP2C19 in the Growth Process: A Novel Case Report.
    Yamaguchi A; Tazawa Y; Ueki M; Yamada M; Manabe A; Sugawara M; Takekuma Y
    Yakugaku Zasshi; 2023; 143(6):545-549. PubMed ID: 37258188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
    Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
    Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
    Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
    J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of voriconazole serum concentrations and safety profile in pediatric oncology patients].
    Silva F; Navea D; Saias C; Torres JP; Catalán P; Morales J
    Rev Chilena Infectol; 2016 Apr; 33(2):127-34. PubMed ID: 27314989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
    Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
    Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
    Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
    Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of switching from intravenous to oral administration on serum voriconazole concentration.
    Harada S; Niwa T; Hoshino Y; Fujibayashi A; Suzuki A
    J Clin Pharm Ther; 2021 Jun; 46(3):780-785. PubMed ID: 33393135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability of voriconazole in hospitalised patients.
    Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC
    Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of Everolimus and Voriconazole Interaction in Lung Transplant Patients.
    Outeda Macías M; Salvador Garrido P; Elberdín Pazos L; Martín Herranz MI
    Ther Drug Monit; 2016 Jun; 38(3):305-12. PubMed ID: 26926669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
    Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
    Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two Different Approaches for Oral Administration of Voriconazole Loaded Formulations: Electrospun Fibers versus β-Cyclodextrin Complexes.
    Siafaka PI; Üstündağ Okur N; Mone M; Giannakopoulou S; Er S; Pavlidou E; Karavas E; Bikiaris DN
    Int J Mol Sci; 2016 Feb; 17(3):282. PubMed ID: 26927072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole Concentrations in Cerebrospinal Fluid During Prophylactic Use in Children with Acute Myelogenous Leukemia.
    Kobayashi R; Sano H; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    Pediatr Infect Dis J; 2016 Mar; 35(3):297-8. PubMed ID: 26650112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh).
    Flammer K; Nettifee Osborne JA; Webb DJ; Foster LE; Dillard SL; Davis JL
    Am J Vet Res; 2008 Jan; 69(1):114-21. PubMed ID: 18167096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
    Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
    J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Necessity for a System Implementing Therapeutic Drug Monitoring in Outpatient Settings Based on the Actual Use of Voriconazole Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan: A Descriptive Epidemiological Study.
    Muraki Y; Koizumi R; Kusama Y; Inose R; Ishikane M; Ohmagari N
    Biol Pharm Bull; 2023; 46(10):1490-1493. PubMed ID: 37779051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and distribution of voriconazole in body fluids of dogs after repeated oral dosing.
    Lemetayer JD; Dowling PM; Taylor SM; Papich MG
    J Vet Pharmacol Ther; 2015 Oct; 38(5):451-6. PubMed ID: 25691353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.